ADMA Biologics
ADMA
306 hedge funds and large institutions have $4.16B invested in ADMA Biologics in 2024 Q3 according to their latest regulatory filings, with 93 funds opening new positions, 103 increasing their positions, 95 reducing their positions, and 39 closing their positions.
1,340% more call options, than puts
Call options by funds: $33.2M | Put options by funds: $2.3M
138% more first-time investments, than exits
New positions opened: 93 | Existing positions closed: 39
105% more capital invested
Capital invested by funds: $2.03B → $4.16B (+$2.14B)
21% more funds holding
Funds holding: 252 → 306 (+54)
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
11.41% more ownership
Funds ownership: 78.14% → 89.56% (+11%)
8% more repeat investments, than reductions
Existing positions increased: 103 | Existing positions reduced: 95
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$305M |
| 2 |
State Street
Boston,
Massachusetts
|
+$76.9M |
| 3 |
Morgan Stanley
New York
|
+$62.2M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$56M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$48.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MF
Magnetar Financial
Evanston,
Illinois
|
-$57.1M |
| 2 |
Nuveen
Charlotte,
North Carolina
|
-$36.5M |
| 3 |
American Century Companies
Kansas City,
Missouri
|
-$28.7M |
| 4 |
PA
Perceptive Advisors
New York
|
-$26.6M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
-$24.8M |
ADMA Hedge Fund Activity: Q3 2024 in Review
306 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in ADMA Biologics (ADMA) for Q3 2024, worth a combined $4.16B — up 105% from $2.03B a quarter earlier.
Buyers outnumbered sellers: 93 funds opened new ADMA positions and 39 closed out — a net gain of 54 holders — while 103 added to existing stakes and 95 trimmed.
The largest buyer was BlackRock, adding an estimated $305M. The largest seller was Magnetar Financial, cutting an estimated $57.1M.
- 306 institutional investors held ADMA Biologics (ADMA) as of Q3 2024, up from 252 in Q2 2024.
- Funds reported $4.16B of ADMA Biologics stock for Q3 2024, up 105% quarter-over-quarter.
- 93 funds opened new ADMA Biologics positions in Q3 2024 and 39 closed out, a net change of +54 holders.
- The largest ADMA Biologics buyer in Q3 2024 was BlackRock, an estimated $305M added.
- The largest ADMA Biologics seller in Q3 2024 was Magnetar Financial, an estimated $57.1M sold.
Based on aggregated 13F filings for Q3 2024.